The EMBO Lab Leadership Course for Postdocs concluded successfully on 13-15 May 2025. A total of 18 postdoctoral researchers participated in the three-day, in-person programme, including six postdocs from the CAMS Oxford Institute (COI).
A new study, led by researchers at the CAMS Oxford Institute in the Nuffield Department of Medicine and TIDU in the MRC Weatherall Institute of Molecular Medicine, has found that specific T cells could have an impact on the long-term protective responses to future infection.
The National Academy of Sciences (NAS) in the US just announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and considered one of the highest honours that a scientist can receive.
We\u2019re pleased to announce that the CAMS Oxford Institute Spatial and Gene Profiling Hub has been formally recognized by Bruker Spatial Biology for its generation of high-quality spatial transcriptomic and proteomic data across its nCounter\u00ae and GeoMx\u00ae Digital Spatial Profiler platforms.
Research is Beautiful campaign continues to inspire with some fantastic images. Congratulations to Dr Matthew Bottomley of the CAMS Oxford Institute, his image shoes a cutaneous squamous cell carcinoma infiltrating into the dermis.
Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine vial.
Dr Pablo F. C\u00e9spedes, CAMS Oxford Institute Career Development Fellow, has received funding from NC3Rs to establish a lymphoid organoid and explant hub at the University of Oxford.
Career Development Fellow Ad\u00e1n Pinto-Fern\u00e1ndez has won the CRUK-Centre for his project titled Targeting ISGylation to Boost Cancer Antigenicity: A Novel Approach for Cancer Immunotherapy
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian biotech innovator Univercells.
Scientists in the Nuffield Department of Medicine and the Icahn School of Medicine at Mount Sinai have developed an innovative antibody platform aimed at tackling one of the greatest challenges in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and evade existing vaccines and therapies.
In a new study, published in NPJ Vaccines, researchers from the Pandemic Sciences Institute and The Pirbright Institute have generated new evidence supporting the development of a universal influenza vaccine.
CAMS Oxford Institute Group Leader and Career Development Fellow, Ad\u00e1n Pinto-Fern\u00e1ndez, has been awarded a highly competitive 2-year project grant by Boehringer Ingelheim through their Open Innovation Portal initiative, opnMe.
The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a \u00a32.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.
120 scientists from across Europe and beyond have been elected to the European Molecular Biology Organization (EMBO) membership, an honour that celebrates research excellence and outstanding achievements in the life sciences, including Dr Peijun Zhang from the Nuffield Department of Medicine.
Sepsis patients could be treated based on their immune system\u2019s response to infection, not their symptoms. New research uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments and lead to the development of targeted therapies.
Globally kidney disease is forecast to be the 5th leading cause of death by 2040, and in the UK more than 3 million people are living with the most severe stages of chronic kidney disease. Chronic kidney disease is often due to autoimmune damage to the filtration units of the kidney, known as the glomeruli, which can occur in lupus, a disease which disproportionally affects women and people of non-white ethnicities, groups often underrepresented in research. Treatment options are limited, can have life threatening side-effects and often don\u2019t slow the disease, which can then progress to end stage, requiring dialysis or a kidney transplant.
Professor Teresa Lambe OBE, Professor Julian Knight & Professor Jane McKeating have been elected as Fellows of the Academy of Medical Sciences, one of the most prestigious awards in the field.
The Centre for Medicines Discovery (CMD) and CAMS Oxford Institute (COI) at NDM, has recently partnered with Ono Pharmaceutical Co (Ono) to validate and develop novel targets in a bid to discover innovative medicines.
![\"\"](\"https://www.camsoxford.ox.ac.uk/news/embo-lab-leadership-course-for-postdocs-successfully-concludes-at-oxford-university-careers-service/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n